Compare VanEck Junior Gold Miners (GDXJ) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Globus Medical Inc. Class A Common Stock — how do they compare? VanEck Junior Gold Miners trades at $106.3 (market cap $8.21B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| GDXJ | GMED | |
|---|---|---|
Market Cap | $8.21B | $10.25B |
Volume | 2,596,073 | 1,108,124 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $96.82 |
52-Week Low | $87.56 | $58.33 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $110.63, down 2.03% on the day amid a bearish technical signal from moving averages. Recent news highlights multiple junior mining companies being added to the ETF's index, potentially increasing its diversification and investor interest. Key technical indicators show mixed signals, with oscillators neutral but moving averages and overall signal leaning bearish.
The outlook for GDXJ is influenced by gold price volatility and the performance of its underlying junior mining holdings. Investment opportunities include exposure to gold's potential upside through leveraged junior miners, but risks involve sector-specific volatility, operational challenges of small-cap miners, and broader market sentiment shifts affecting gold prices.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
